Resources
83 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/3/2019 (updated 3/25/2024)
Findings suggest that many North Carolina LEOs understand the public health benefits of syringe access programs and may be inclined to support syringe decriminalization legislation.
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 11/19/2019 (updated 3/25/2024)
The document provides guidance on how to plan for an outbreak of HIV or HCV among PWID including considerations for developing an outbreak response plan to minimize the impact of the outbreak on the community and stop further transmission. The document also outlines strategies to detect and investigate a possible outbreak.
Posted 7/28/2023 (updated 3/26/2024)
The Rural Health Information Hub's (RHIhub) article covers best practices and emerging models for rural harm reduction programs. Among those featured in the article is the RCORP-TA grantee, the South Dakota State University's program Stigma, Treatment, Avoidance and Recovery in Time - South Dakota (START-SD).
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/29/2023 (updated 3/26/2024)
This engaging webinar provided an overview of an invaluable resource that harnesses the wisdom of dozens of harm reduction experts. "Harm Reduction Hacks" offers important insights, tips, and tricks.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs